Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients.

ABSTRACT:

Background

Invasive fungal infections can cause serious complications after lung transplant; therefore, prophylaxis with posaconazole is common. The posaconazole delayed-release (DR) tablet is preferred. Although the package insert states DR tablets cannot be crushed, recent data suggest it is reasonable. We hypothesized that crushed posaconazole DR tablets could reach therapeutic levels in lung transplant recipients.

Methods

A retrospective study of lung transplant recipients between January 2018 and July 2023, who received crushed posaconazole DR for at least 5 days was completed. Posaconazole troughs were evaluated, and differences were compared between subjects who were therapeutic to those who were subtherapeutic. A cost analysis was also performed.

Results

Thirt

SUBMITTER: Gordon R 

PROVIDER: S-EPMC11827724 | biostudies-literature | 2025 Jan-Feb

REPOSITORIES: biostudies-literature